Vigilare Wealth Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Vigilare Wealth Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,800	Closed	-$31.4K	–	94
2023 Q1	$31.4K	Hold	28,800	–	–	0.02%	103
2022 Q4	$42K	Sell	28,800 -8,000	-22%	-$13K	0.02%	105
2022 Q3	$40K	Sell	36,800 -5,000	-12%	-$9.19K	0.05%	103
2022 Q2	$71K	Buy	+41,800	New	+$71.8K	0.08%	107
2022 Q1	–	Sell	-98,450	Closed	-$369K	–	138
2021 Q4	$369K	Sell	98,450 -1,500	-2%	-$6.83K	0.22%	116
2021 Q3	$517K	Buy	99,950 +45,700	+84%	+$205K	0.32%	87
2021 Q2	$231K	Buy	54,250 +16,850	+45%	+$81.8K	0.14%	181
2021 Q1	$199K	Buy	37,400 +19,900	+114%	+$114K	0.14%	187
2020 Q4	$94K	Buy	+17,500	New	+$95.1K	0.09%	147

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vigilare Wealth Management's ADAP Position: Q2 2023 in Review

Vigilare Wealth Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2023, closing a stake of 28,800 shares — an estimated $31.4K sold.

Vigilare Wealth Management first reported a position in ADAP in Q4 2020 and held it in 9 quarters. The position peaked at $517K in Q3 2021. 89 funds tracked by Wall St. Rank hold ADAP as of Q2 2023.

Vigilare Wealth Management reported no remaining Adaptimmune Therapeutics position as of Q2 2023 after selling out during the quarter.
Vigilare Wealth Management sold 28,800 Adaptimmune Therapeutics shares in Q2 2023, an estimated $31.4K.
Vigilare Wealth Management first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 9 quarters.
Vigilare Wealth Management's Adaptimmune Therapeutics position peaked at $517K in Q3 2021.
89 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2023.

Based on Vigilare Wealth Management's 13F filing for Q2 2023, filed 11 Jul 2023.